Table 1.

Examples of targeted ablative strategies in use or development

	Therapy	Example	Target	Stage
Non-specifically targeted	all hematopoietic cells	total body irradiation	all hematopoietic cells	clinic
Cell-specific targeted	anti-idiotype	customized	clonal population of cells (lymphoma)	clinic
	chemical inhibitors	Gleevec1	specific tumor cells bearing BCR/ABL protein	clinic
	anti-CD20	Rituxan2, Zevalin3	mature B cells	clinic (GENE, IDEC)
	anti-CD30	MDX-06044, SGN-3055	activated B cells (NHL cells)	phase II (MEDX, SGEN)
	anti-CD52	Campath6	mature lymphocytes	clinic
	anti-CD80	Galiximab7	activated B cells (NHL cells)	phase III
	anti-CD23	Lumiliximab8	late transitional and mature B cells (B-CLL)	phase II
	anti-CD40	SGN-409	antigen-presenting cells (CLL and NHL)	phase I/II
Homeostasis regulator targeted	anti-BLyS/TACI-Ig/	Belimumab10	cytokine required for B	phase III (HGS/GSK), phase I (AMG, IDEC/GENE, ZGEN)
	/BR3-Fc/anti-BR3	AMG-62311, Atacicept12, anti-BR313	cell survival
	anti-APRIL		cytokine required for B cell survival

¹Novartis, reviewed in ref. [152];

²Genentech, reviewed in ref. [147];

³Biogen Idec, reviewed in ref. [148];

⁴Medarex, reviewed in ref. [145];

⁵Seattle Genetics, reviewed in ref. [154];

⁶Ilex, reviewed in ref. [144];

⁷Biogen Idec, reviewed in ref. [149];

⁸Biogen Idec, reviewed in ref. [153];

⁹Seattle Genetics reviewed in ref. 150];

¹⁰Human Genome Sciences, reviewed in ref. [146];

¹¹Amgen, unpublished;

¹²Zymogenetics/Serono, reviewed in ref. [151];

¹³Biogen Idec, unpublished.

B-CLL – B cell chronic lymphocytic leukemia.